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Abstract We have evaluated the role of the HLA-DRB1*1501 allele and the IL-2 −330 T/G 
polymorphism and their interaction in susceptibility to multiple sclerosis on 360 patients and 426 
matched healthy individuals. We used the SSP-PCR method to determine the alleles. Fisher's 
exact test was used to analyses. We observed a significant increase in the T allele at IL-2 −330 
position in patients (OR = 1.34, Pb0.05), and the T/T and T/G genotypes were more frequent 
among patients than controls. The HLA-DRB1*1501 allele was overrepresented in patients as 
compared to the control group (OR=1.7, P =0.0006). The two-locus analysis of the interaction 
between the IL-2 promoter polymorphism and the HLA-DRB1 allele showed that the HLA­
DRB1*1501/T haplotype was more frequent in patients than controls (OR =16, Pb 0.0001). Our 
findings support previous findings about the role of the HLA-DRB1*1501 allele in susceptibility to 
MS. This work also provides new findings about the importance of gene–gene interactions in the 
development of MS. 
© 2010 Elsevier Inc. All rights reserved. rosis. 
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135 High frequency of the IL-2 −330 T/HLA-DRB1*1501 haplotype in patients with multiple sclerosis Introduction 
Multiple sclerosis (MS) is a challenging disorder for neuroscience 
researchers because of the complexity of its pathophysiology. 
Although the triggering event is not yet understood, however, it 
is known that activation of the immune system against self 
myelin antigens is a common process that occurs in the course of 
this disease. There is also evidence supporting the presence of 
self-reacting immune components, i.e., the complement 
system, antibodies and lymphocytes, in MS patients [1,2]. 
There is no doubt that genetic polymorphisms are involved 
in susceptibility to MS [3–5]. HLA alleles and haplotypes might 
be the most relevant genetic predisposing factors for multiple 
sclerosis [6,7]. Fernández et al. [8] found a significant 
association between the HLA-DRB1*1501 allele, as well as 
some haplotypes that included this allele, and MS. A recent 
publication by the ANZ consortium revealed similar results in a 
large population [9]. 
The cytokine network is a cornerstone of the human 
immune system. Activation of the cytokine network, whether 
primary or secondary, results in complex connections that 
determine the course of the disease. Some believe that 
multiple sclerosis is a result of dysregulation of the immune 
response. There is evidence that the immune system shifts 
from Th2 to Th1 in MS patients [10]. 
Interleukin 2 (IL-2) is an important cytokine that is 
produced by activated T cells and promotes the proliferation 
of lymphocytes, macrophages and NK cells [11,12]. It has 
both pro- and anti-inflammatory activities. It promotes an 
inflammatory response through the generation of Th1 and 
Th2 effector cells. It also blocks the differentiation of T cells 
into Th17 effectors and promotes the development and 
maintenance of T regulatory cells (reviewed in [13]). 
The relevance of IL-2 in multiple sclerosis had been 
elucidated by studies of MS patients and experimental 
autoimmune encephalomyelitis (EAE) [14,15]. Levels of IL-2 
mRNA were increased in CNS lesions of EAE models during the 
acute phase [15]. 
A single nucleotide polymorphism (SNP) at the −330 
position of the IL-2 gene was identified by John and colleagues 
[16]. According to a study by Hoffmann et al. [17], stimulation 
with anti-CD3/CD28 induced higher levels of IL-2 in individuals 
who were homozygous for the G allele relative to those who 
had the G/T or T/T genotypes. However, there is disagreement 
about the impact of this SNP on the production of IL-2 [18]. 
Matesanz et al. [19] reported that the G/T and T/T 
genotypes at the −330 position of the human IL-2 promoter 
are associated with susceptibility to MS. However, Shokrgozar 
and colleagues [20] did not observe a significant association 
between the IL-2 −330 SNP and susceptibility to MS. 
The aim of this study was to assess the frequencies of the 
IL-2 −330 T and G alleles among Iranian MS patients and 
healthy individuals as well as the interaction between these 
genotypes and the HLA-DRB1*1501 allele. 
Materials and methods 
Subjects 
We studied the distribution of IL-2 −330 allele and genotypes 
and the HLA-DRB1*1501 allele in 360 unrelated MS patients from a single center and 426 healthy controls to evaluate the 
impact of these variations and their interaction on suscep­
tibility to MS. Expert neurologists confirmed the occurrence 
of MS according to clinical and paraclinical findings (MRI, 
oligoclonal bands in CSF and evoked potentials) based on 
McDonald's criteria [21]. Age-, sex- and ethnicity-matched 
control subjects with no history of autoimmune or inflam­
matory disorders were selected from the northeast of Iran in 
order to preclude environmental factors. A demographic 
questionnaire that included sex and age for both groups and 
the type of MS, age at onset and the Expanded Disability 
Status Scale (EDSS) for MS patients was prepared. The study 
was performed with the approval of the local ethics 
committee, and informed consent was obtained from all 
recruited individuals. None of the approached subjects 
refused to participate. 
Themean agewas 31±9 years for MS patients (ranging from 
19 to 57 years old) and 39±7 years for control subjects (ranging 
from 35 to 64 years old). The mean age of onset and EDSS were 
26±6 years (10–46 years old) and 3.5±2 (ranging from 1 to 8), 
respectively. The female/male ratio in the patient group was 
5:1. According to clinical subtypes, 306 patients (85%) had 
relapsing-remitting MS and 43 (12%) had primary-progressive 
MS. There were also eight patients with secondary-progressive 
MS and three with progressive-relapsing MS. DNA extraction and genotyping 
Genomic DNA was extracted from 10 ml of peripheral whole 
blood by a standard protocol with some modifications [22]. 
Briefly, red blood cells were lysed three times with a buffer 
containing ammonium chloride, potassium dihydrogen phos­
phate and disodium hydrogen phosphates. SDS (10%), EDTA 
and 10 μl proteinase K were then added to the pellet, which 
was incubated for 1 hour at 65 °C. After incubation, a phenol/ 
chloroform/isoamyl alcohol mix was added to samples, which 
were then centrifuged. To visualise and precipitate the DNA, 
isopropanol and sodium acetate were added to the superna­
tant and DNA was extracted after centrifugation. DNA 
samples were aliquoted in graded distilled water, and DNA 
concentrations were determined by a UV spectrophotometer 
at 260 nm (Techne, UK). All samples were diluted and stored 
at −80 °C for future analysis. 
To detect the IL-2 polymorphism at −330 position, 
multiplex SSP-PCR was performed according to Reynard 
and colleagues [23]. The HLA-DRB1*1501 Genotyping was 
carried out by methods and primers previously described [24] 
in a thermocycler (Techne, UK). The PCR products were 
electrophoresed on a 2% agarose gel (Merck, Germany), and 
bands were visualised with a gel documentation system 
(UVITEC, UK). Statistical analysis 
Data were recorded in the program SPSS v-16, and the means 
of parametric variables were calculated. Data are presented 
as means±SD for parametric variables and as percentages for 
non-parametric variables. Allele and genotype frequencies 
were calculated and compared between groups by non­
parametric tests followed by Fisher's exact analysis using 
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Table 1 Frequencies of IL-2 −330 alleles and genotypes in 
patients and control subjects. 
MS Control OR CI P-value 
Allele 
G 262 (36%) 375 (44%) 1 — — 
T 458 (64%) 477 (56%) 1.34 1.1–1.7 0.0047 
Genotypes 
G/G 14 (4%) 68 (16%) 1 — — 
G/T 234 (65%) 239 (56%) 4.76 2.6–9.4 b0.0001 
T/T 112 (31%) 119 (28%) 4.6 2.4–9.3 b0.0001 
MS=multiple sclerosis; OR =odds ratio; 95% CI =95% confidence 
interval. STATA v-8 (CA, US). P-values were determined, and those 
less than 0.05 were considered to be significant. 
Results 
The frequency of the T allele at the IL-2 −330 SNP position was 
significantly higher in MS patients than in controls (OR =1.34, 
95% CI =1.1–1.7, P =0.0047). Furthermore, the G/T and T/T 
genotypes were more frequent in patients than in control 
subjects. Complementary data are shown in Table 1. The IL-2 
−330 SNP did not show any significant impact on the age at 
onset or the EDSS of MS patients (data not shown). 
In the IL-2 −330 position, the T allele was present in 96.2% 
of patients and 84.4% of healthy individuals (OR =4.7, 95% 
CI= 2.6–9.2, P b 0.0001) (Table 2). 
Of 360 patients, 107 (45.1%) carried the HLA-DRB1*1501 
allele, which was significantly higher than that in healthy 
controls (Table 2). The age at onset and EDSS were not 
significantly different between HLA-DRB1*1501-positive and 
HLA-DRB1*1501-negative patients. 
The haplotype containing both the HLA-DRB1*1501 and IL-2 
−330 T alleles showed a higher frequency in MS patients than in 
the general population. Data on the frequencies of these 
haplotypes are shown in Table 2. 
Discussion 
We have studied the IL-2 −330 T/G SNP and the HLA­
DRB1*1501 allele in Iranian MS patients and healthy controls. Table 2 Frequencies of risk alleles (IL-2 −330 T and HLA-DRB1*1
Comparison MS Cont
T+ vs. T− 346 (96%) 14 (4%) 358 
DR15+ vs. DR15− 166 (46%) 194 (54%) 144 
T+/DR15+ vs. T+/DR15− 156 (43%) 190 (53%) 129 
T+/DR15+ vs. T−/DR15+ 156 (43%) 10 (3%) 129 
T+/DR15+ vs. T−/DR15− 156 (43%) 4 (1%) 129 
T+/DR15− vs. T−/DR15+ 190 (53%) 10 (3%) 229 
T+/DR15− vs. T−/DR15− 190 (53%) 4 (1%) 229 
T−/DR15+ vs. T−/DR15− 10 (3%) 4 (1%) 15 
MS=multiple sclerosis; OR =odds ratio; 95% CI =95% confidence intervaOur results show that the IL-2 −330 T allele and the G/T and 
T/T genotypes were associated with a higher risk of 
developing MS. Furthermore, when combined with the HLA­
DRB1*1501 allele, the IL-2 T allele was strongly associated 
with susceptibility to MS. 
In our study, significantly more patients (46%) than 
controls (34%) were positive for the HLA-DRB1*1501 allele. 
The prevalence of this allele was 46% in a previous study on 
an Iranian MS population [24]. This rate was found to be 
38.6% in Basque, Spain [8]. Chao and colleagues [25] found 
that some HLA-DRB1*15 haplotypes determined susceptibil­
ity to MS while others did not. They concluded that HLA­
DRB1*15 is part of a susceptibility haplotype but cannot be 
the susceptibility allele itself as it requires the further 
contribution of either epistatic interactions, epigenetic 
modifications or nearby structural variations [25]. 
The implication of IL-2 in the pathogenesis of multiple 
sclerosis is well documented [26]. The first evidence 
supporting the effect of the IL-2 −330 SNP on susceptibility 
to MS was provided by Matesnaz et al. [19]. They concluded 
that the G/T and T/T genotypes at this position were 
associated with a higher risk of developing MS [19]. 
Amirzargar et al. [27] reported controversial findings in an 
Iranian population; they found that the IL-2 −330 G/G 
genotype was more frequent among MS patients. In another 
study by Kikuchi and colleagues [28], the frequencies of the 
IL-2 −330 alleles and genotypes were not significantly 
different between Japanese MS patients and healthy 
controls. More recently, Shokrgozar et al. [20] reported 
that the frequencies of genotypes at position −330 did not 
differ significantly between Iranian MS patients and controls. 
Most of these studies were performed on a small number of 
samples, and it seems that large population studies are 
needed to provide more reliable results. 
There are controversial reports of the impact of the IL-2 
−330 SNP on the production of this cytokine [17,18]. In one 
study, Matesnaz and colleagues [18] evaluated the expres­
sion of the IL-2 −330 G and T alleles in vivo and in vitro. This 
transfection study, which was performed in Jurkat cells, 
demonstrated differential promoter activity between the G 
and T alleles. The promoter with the G allele was twice as 
active as the one with the T allele. Conversely, quantifica­
tion of allelic expression in lymphocytes showed that the 
−330 T allele was associated with a higher level of 
transcription than the −330 G allele. They also found higher 
levels of IL-2 mRNA expression in samples of individuals with 
−330 T/T and G/T genotypes compared to individuals with 501) in patients and control subjects. 
rol OR 95% CI P-value 
(84%) 68 (16%) 4.7 2.6–9.2 b0.0001 
(34%) 282 (66%) 1.7 1.2–2.3 0.0006 
(30%) 229 (54%) 1.5 1.1–2.0 0.0172 
(30%) 15 (4%) 1.8 0.7–4.7 NS 
(30%) 53 (12%) 16.0 5.6–62.2 b0.0001 
(54%) 15 (4%) 1.2 0.5–3.2 NS 
(54%) 53 (12%) 11.0 3.9–42.4 b0.0001 
(4%) 53 (12%) 8.8 2.1–42.8 0.0007 
l. 
137 High frequency of the IL-2 −330 T/HLA-DRB1*1501 haplotype in patients with multiple sclerosis 
 the −330 G/G genotype [18]. They suggested that the 
difference between the in vivo and in vitro influence of the 
−330 IL-2 promoter polymorphic site suggested the existence 
of additional, unknown polymorphisms that affect gene 
regulation [18]. 
Marrosu et al. [29] suggested that the MHC gene(s) might 
be primarily responsible for genetic susceptibility to MS. 
They also noted that the presence of complex interactions 
between different HLA haplotypes, other non-HLA predis­
posing genes and environmental factors might explain 
different associations in different populations [29]. It is
well documented that HLA alleles may influence other genes 
in the pathogenesis of MS [30]. The lack of data on the effects 
of combinations of the IL-2 SNPs and HLA-DRB alleles on MS 
elucidates the need for such a study. 
This study provides the first evidence that there is an 
interaction between the HLA-BRD1*1501 allele and the IL-2 
−330 T allele in susceptibility to MS. Individuals carrying both 
the IL-2 −330 T and HLA-DRB1*1501 alleles had 16 times 
higher susceptibility to MS relative to those lacking both. 
Furthermore, having only one of these alleles was associated 
with approximately 9 to 11 times increased susceptibility to 
MS relative to having neither allele. 
In conclusion, our study revealed that the IL-2 −330 T 
allele and the G/T and T/T genotypes were associated with a 
higher risk of developing MS in the studied population. In 
accordance with many previous reports, the HLA-DRB1*1501 
allele was associated with a higher risk of developing MS in 
the studied population. We have provided evidence of an 
interaction between the IL-2 −330 T and HLA-DRB1*1501 
alleles in the genetic susceptibility to MS. Acknowledgments 
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